Sarepta Therapeutics Inc.


Baird Bullish on Sarepta Therapeutics Inc (SRPT) Amid DMD Franchise Expansion Deal

Tuesday, Sarepta Therapeutics Inc (NASDAQ:SRPT) and Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) announced a deal that will grant Sarepta European commercialization rights for Summit’s …

Canaccord Boosts Price Target on Summit Therapeutics PLC (ADR) (SMMT) Following Collaboration Agreement with Sarepta Therapeutics Inc (SRPT)

Yesterday, Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) announced a collaboration and license agreement, which will grant Sarepta Therapeutics Inc (NASDAQ:SRPT) European Union commercialization rights …

William Blair Bullish on Sarepta Therapeutics Inc (SRPT) Amid First Patient Dosing in Phase III Trial and Catabasis Partnership

On Wednesday, Sarepta Therapeutics Inc (NASDAQ:SRPT) announced that it has dosed the first patient in the Phase III ESEENCE trial for patients with …

Company Update (NASDAQ:SRPT): Sarepta Therapeutics Inc and Catabasis Pharmaceuticals Announce a Joint Research Collaboration in Duchenne Muscular Dystrophy

Sarepta Therapeutics Inc (NASDAQ:SRPT) and Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) announced a joint research collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy (DMD).

Company Update (NASDAQ:SRPT): Sarepta Therapeutics Inc Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 and SRP-4053

Sarepta Therapeutics Inc (NASDAQ:SRPT) announced the first patient dosed in the phase III clinical trial of SRP-4045 and SRP-4053 in patients with Duchenne muscular …

Company Update (NASDAQ:SRPT): Sarepta Therapeutics Inc Announces Pricing of $300 Million Public Offering of Common Stock

Sarepta Therapeutics Inc (NASDAQ:SRPT) announced that it has priced an underwritten public offering of an aggregate of 5.02 million shares of its common stock …

William Blair Weighs in on Sarepta Therapeutics Inc (SRPT) Following Favorable Decision in Patent Appeal

Sarepta Therapeutics Inc (NASDAQ:SRPT) announced yesterday that the Patent Trial and Appeal Board issued two favorable decisions for Sarepta over an intellectual property and …

Company Update (NASDAQ:SRPT): Sarepta Therapeutics Inc Announces Favorable USPTO Decisions in Exon 51 and Exon 53 Composition of Matter Patent Interference Cases against BioMarin

Sarepta Therapeutics Inc (NASDAQ:SRPT) announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) has issued …

William Blair Upgrades and Bumps Up Price Target on Sarepta Therapeutics Inc (SRPT) Following FDA Accelerated Approval

On Monday, September 19th, the FDA granted accelerated approval to Sarepta Therapeutics Inc (NASDAQ:SRPT) pipeline drug eteplirsen (Exondys 51), designed to treat exon …

Analysts Dive in on Two Volatile Biotech Stocks: Sarepta Therapeutics Inc (SRPT), Vical Incorporated (VICL)

It has been an explosive twenty-four hours in the biotech-verse, as analysts are prompted to offer insights on Sarepta Therapeutics Inc (NASDAQ:SRPT), with shares shooting …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts